COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Solana Company Files Application to Cease to Be a Reporting Issuer in Canada
04/11/2025
NEWTOWN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (“ Solana ” or the “ Company ”) today announced that it has applied to the British Columbia Securities Commission, as principal regulator, [...]
Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call
04/11/2025
CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced it will release financial results for the [...]
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
04/11/2025
On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease [...]
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
04/11/2025
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
04/11/2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and [...]
Revolution Medicines to Participate in November 2025 Investor Conferences
04/11/2025
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Amwell® Announces Results for Third Quarter 2025
04/11/2025
BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third [...]
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2025
04/11/2025
DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
04/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
04/11/2025
- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at [...]
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
04/11/2025
SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
04/11/2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it [...]
Clover Health Reports Third Quarter 2025 Results
04/11/2025
Business Highlights: Generates third quarter year-to-date positive Adjusted EBITDA profitability, on a wide network, while growing membership by 35% and revenue by 39% year-over-year, despite a greater proportion of new [...]
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04/11/2025
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual [...]
Standard BioTools Reports Third Quarter 2025 Financial Results
04/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. [...]
OnKure Therapeutics to Participate in Upcoming Investor Conferences
04/11/2025
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that [...]
OrthoPediatrics to Participate in Upcoming Conferences
04/11/2025
WARSAW, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, a company focused [...]

Pages